SorCS3 does not require propeptide cleavage to bind nerve growth factor  by Westergaard, U.B. et al.
FEBS Letters 579 (2005) 1172–1176 FEBS 29259SorCS3 does not require propeptide cleavage to bind nerve growth factor
U.B. Westergaarda, K. Kirkegaarda, E.S. Sørensenb, C. Jacobsena, M.S. Nielsena,
C.M. Petersena,*, P. Madsena,*
a Institute of Medical Biochemistry, Ole Worms Alle´, bldg. 170, University of Aarhus,
8000 Aarhus C, Denmark
b Protein Chemistry Laboratory, Department of Molecular Biology, Gustav Wieds Vej 10C, University of Aarhus, 8000 Aarhus C, Denmark
Received 9 November 2004; revised 2 December 2004; accepted 23 December 2004
Available online 19 January 2005
Edited by Lukas HuberAbstract The functional properties of the Vps10p-domain
receptor SorCS3 are undescribed. Here, we examine its process-
ing and sorting in cellular transfectants, and analyze the binding
of potential ligands to the puriﬁed receptor. We show that
SorCS3 is synthesized as a proprotein and converted to its ma-
ture form by N-terminal propeptide cleavage in distal Golgi com-
partments. The propeptide is not a requirement for normal
processing of the receptor and does not prevent ligands from
binding to the SorCS3 precursor form. Expression of wt and chi-
meric receptors further suggests that SorCS3 predominates on
the plasma membrane, exhibits slow internalization and does
not engage in intracellular traﬃcking. SorCS3 emerges as a
new neurotrophin binding Vps10p-domain receptor functionally
distinct from its relatives Sortilin and SorLA.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The ﬁve transmembrane proteins Sortilin, SorLA and
SorCS1-3 [1–5] constitute a family of heterogeneous type-1
receptors that are particularly expressed in embryonic and
adult neuronal tissue [6–9]. Each receptor is characterized by
having a single, N-terminal copy of the so-called Vps10p-
domain, a domain-type not found in other mammalian
proteins, and originally identiﬁed in the yeast vesicular sorting
protein Vps10p [10]. The Vps10p-domain is the only ectodo-
main in Sortilin, whereas the other four family members have
more composite luminal parts. Thus, SorLA comprises struc-
tural elements typical of the low density lipoprotein receptor
as well as a domain of ﬁbronectin type III repeats, and
SorCS1-3 contains a leucine-rich segment bordering the trans-
membrane domain. Apart from the ectodomains, each recep-Abbreviations: s-SorCS3, luminal part of SorCS3 as secreted minire-
ceptor; s-SorCS3pro-mut, cleavage-resistant minireceptor; TGN, trans-
Golgi network; NGF, nerve growth factor; proNGF, proform of
NGF; NGFpro, propeptide of proNGF; IL2R, interleukin 2 receptor;
cd, cytoplasmic domain
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doi:10.1016/j.febslet.2004.12.088tor has a short cytoplasmic domain (cd; 50–80 amino acids)
and, at least in Sortilin and SorLA, the cds contain functional
sites (e.g., dileucines, acidic clusters and tyrosine-based signals)
for endocytosis as well as intracellular traﬃcking [11–13]. The
N-termini of mammalian Vps10p-domains comprise dibasic
target-motifs for proprotein convertase activity and are func-
tionally important propeptides in Sortilin and SorLA. The
two receptors bind their respective propeptides, which in re-
turn prevents binding of other ligands, and they therefore de-
pend on propeptide cleavage for full functional activity [12,14].
Following cleavage, the mature receptors convey binding and
endocytosis of a variety of ligands, e.g., neurotrophins, lipo-
protein lipase and neurotensin [12,15–17], but may also target
proteins in the biosynthetic pathway for Golgi-endosome
transport [11,18]. Moreover, Sortilin in complex with p75NTR
interacts with the proform of nerve growth factor-b (proNGF)
and is essential to proNGF-mediated induction of neuronal
death [16]. This suggests that Vps10p-domain receptors may
also partake in transmembrane signalling and adds to the pic-
ture of a multifunctional receptor family.
In contrast to Sortilin and SorLA little is known about the
SorCS molecules that form a subgroup of particularly closely
related Vps10p-domain receptors. SorCS1, which is expressed
as diﬀerent isoforms with alternative cds, appears to be in-
volved in diﬀerential, isoform-dependent traﬃcking in cells
[19]. Recent ﬁndings further demonstrate that although it is
subject to propeptide cleavage it does not bind its own propep-
tide [19], a ﬁnding that might reﬂect a diﬀerence between the
functional organization of the SorCS proteins and that of Sor-
tilin and SorLA. However, SorCS-speciﬁc ligands have not
been identiﬁed, the role of the propeptide is unclariﬁed and
functional expression of SorCS1 and -2 has not been described.
The present studywas undertaken to provide new information
on the molecular function of the SorCS-subgroup. We have
examined theprocessing and traﬃcking of SorCS3 in transfected
cells by expression of wt SorCS3 and of chimeric receptors car-
rying the SorCS3 cytosolic domain. In addition, we have tested
potential ligands for binding to puriﬁed SorCS3 and analyzed
the ligand binding activity of its uncleaved precursor.2. Materials and methods
2.1. DNA constructs
The coding sequence of human full-length SorCS3 (M41–V1181) was
excised from the original KIAA 1059 cDNA clone (Genbank Accession
No. AB028982) [5] and ligated into the pcDNA3.1/zeo() expression
vector (Invitrogen). SorCS3 without its transmembrane and cdsblished by Elsevier B.V. All rights reserved.
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SorCS3)) was constructed from the original cDNA and expressed using
the pcDNA4/myc-his C expression vector (Invitrogen). Cleavage-resis-
tant minireceptor (s-SorCS3pro-mut) was generated by site-speciﬁc muta-
tions in the propeptide cleavage motif (R88RSRR92/R88RSGG92) and
expressed in pcDNA4/myc-his C. Chimeric receptors (IL2R/SorCS3)
combining the luminal and transmembrane domains of interleukin 2
receptor (IL2R) (CD25/Tac) or cation-independent mannose 6-phos-
phate receptor (MPR300)with the cd (wt ormutant) of SorCS3was con-
structed and inserted into the pcDNA3.1/zeo() vector as described [11].
Human nerve growth factor-b (NGF) was from Austral Biologicals,
brain-derived neurotrophic factor (BDNF), neurotrophin3 (NT3), neu-
rotrophin4/5 (NT4), neurturin and glial cell-line derived neurotrophic
factor (GDNF)were fromR&DSystems, andneurotensinwas fromSig-
ma. The prodomain-coding regions of human NGF (E1–R102), BDNF
(S40–R108),NT3 (N1–R79),NT4 (S1–R56), neurturin (I1–R76) andGDNF
(F1–R58) were ampliﬁed from the Genbank-clones AW770784,
AI242172, AA448311, BC012421 and AW050617, or GDNF from
cDNA generated from fetal brain by RT-PCR. The peptides were ex-
pressed in Escherichia coli BL21 as GST-fusion proteins and puriﬁed
using glutathione–Sepharose beads (Amersham Biosciences). Recep-
tor-associated protein (RAP) was generated as described [20] and the
NGF precursor (proNGF) was a gift from Scil Proteins Gmbh.
2.2. Cells and transfection
CHO-K1 cells were cultured in serum-free HyQ-CCM5medium (Hy-
Clone, Logan UT) and mouse embryonic ﬁbroblasts deﬁcient in both
mannose 6-phosphate receptors [21] were grown in Dulbeccos modiﬁed
eagles medium with 10% fetal calf serum. Cells were transfected using
FuGENE 6 (Roche). Stable transfectants were selected at 500 lg/ml
Zeocin and identiﬁed by Western blotting using a mouse anti-IL2R
(anti-CD25/Tac; Roche) and a rabbit antibody raised against a peptide
segment (P137–T234) in the luminal part of SorCS3. s-SorCS3and s-SorC-
S3pro-mut were puriﬁed using TALON-matrix aﬃnity chromatography.
b-Hexosaminidase activity in medium and cell lysates was determined
as described [22]. Mannose 6-phosphate was from Sigma.
2.3. Biolabelling and precipitation
Metabolic cell labelling was performed with L-[35S]-methionine and
L-[35S]-cysteine (pro-mix, Amersham Biosciences) in Met and Cys-
free medium at 100 lCi/ml and 10 lg/ml brefeldin A (BFA, Sigma).
After 2–5 h, the cells were washed and reincubated in unsupplemented
HyQ-CCM5 medium. At given times, incubation was stopped and la-
belled SorCS3 constructs were precipitated from the medium and/or
cell lysates using Gammabind G-Sepharose beads (Amersham Biosci-
ences) coated with anti-SorCS3 antibodies [23]. Following wash, the
beads were resuspended in reducing sample buﬀer (20 mM dithiothre-
itol, 2.5% SDS) either immediately or after treatment with 2.5 U N-gly-
cosidase F (PNGase-F; Roche) or 20 mU Endoglycosidase H
(Endo-H; Boehringer) as described. Boiled samples were analyzed by
SDS–PAGE and autoradiography.Fig. 1. Propeptide cleavage of the secretable minireceptor s-SorCS3
(A) and of full-length SorCS3 in CHO-transfectants (B). The cells were
biolabelled in the presence of BFA prior to wash, reincubation in
unsupplemented medium and chase of labelled receptors. At the times
indicated, labelled receptors were immuno-precipitated from medium2.4. Immunocytochemistry and internalization
CHO cells expressing IL2R/SorCS3 chimeras were cultured on cover
slides and incubated (2 h, 4 C) with mouse anti-IL2R prior to wash
and reincubation in prewarmed medium. At given time points the cells
were ﬁxed (4% formaldehyde, pH 7), permeabilized (0.5% Triton X-
100) and stained with Alexa 488 conjugated goat anti-mouse Ig
(Molecular Probes). Staining was analyzed by confocal microscopy
(LSM510, Carl Zeiss, Germany). Quantization of IL2R/SorCS3-recep-
tor mediated internalization of 125I-labelled anti-IL2R was performed
as previously described [16]. To determine the relative amount of
SorCS3 that was expressed on the plasma membrane, transfected cells
were biotinylated with the membrane-impermeable sulfo-N-hydroxy-
succinimidobiotin. After cell lysis and precipitation with streptavi-
din–Sepharose, the relative amounts of surface-associated
(biotinylated and precipitable) receptors and of intracellular (not pre-
cipitated) SorCS3 were estimated by Western blotting as described [15].and cell lysates (A) or from cell lysates only (B). Untreated precip-
itates, and samples treated with PNGase-F or Endo-H were subse-
quently analyzed by SDS–PAGE. Autoradiographs of 8–16% gels are
shown. Panel C shows a schematic presentation of full-length SorCS3.
The positions of the propeptide cleavage site and the transmembrane
segment are indicated.2.5. BIAcore
Surface plasmon resonance measurements were performed on a Bia-
core 2000 instrument (Biacore, Uppsala, Sweden) equipped with CM5
sensor chips activated as described [14]. s-SorCS3 and s-SorCS3pro-mutwere immobilized to densities 62–82 fmol/mm2 and samples for bind-
ing (40 ll) were injected at 5 ll/min at 25 C in 10 mM HEPES,
150 mM NaCl, 1.5 mM CaCl2, 1 mM EGTA, and 0.005% Tween 20,
pH 7.4. Binding was expressed in relative response units as the re-
sponse obtained from the ﬂow cell with immobilized receptor minus
the response obtained when using an activated but uncoupled chip.
The overall Kd values were determined by BIAevaluation 3.0 software
using a Langmuir 1:1 binding model and simultaneous ﬁtting to all
curves in the concentration range considered (global ﬁtting).3. Results
3.1. SorCS3 is synthesized as a proreceptor
The N-terminal part of SorCS3 contains a classical se-
quence-motif for furin-mediated cleavage, suggesting that
SorCS3 similar to other examined Vps10p-domain receptors,
is synthesized as a precursor molecule. To examine this, s-
SorCS3 minireceptors secreted into the medium or contained
in the cells, were precipitated from cultures of biolabelled
CHO-transfectants. The SDS–PAGE analysis (Fig. 1A) shows
that in deglycosylated samples, but not in untreated samples, s-
SorCS3 from the medium was less retained in the gel than
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creted species. Similar results were obtained by chase experi-
ments in cells expressing full-length SorCS3 (Fig. 1B). It
appears that nearly all newly synthesized receptors were con-
verted from the pro- to the mature form within 3 h (PNG-
ase-panel). The results further show that after 60 min, when
all receptors are resistant to Endo-H, only 50% have been
converted, which strongly suggests that cleavage takes place
in late Golgi-compartments.
N-terminal sequencing of s-SorCS3 puriﬁed from culture
supernatants conﬁrmed cleavage between R92 and A93 and
thus establishes G1–R92 as the SorCS3 propeptide.Fig. 2. Binding of mature NGF, the NGF prodomain (GST-fusion
protein) and the uncleaved proform of NGF to the luminal part of
SorCS3. Puriﬁed s-SorCS3 was immobilized on chips and binding at
pH 7.4 of various concentrations of ligands in solution was determined
by plasmon resonance analysis. Estimated Kd-values are given. The
purity of the s-sorCS3 preparation was veriﬁed by reducing SDS–3.2. SorCS3 binds NGF and its prodomain
Binding of potential ligands to immobilized puriﬁed
s-SorCS3 was assessed by plasmon resonance analysis. A series
of known Sortilin and SorLA Vps10p-domain ligands and re-
lated proteins/peptides were tested. Initial experiments demon-
strated that unlike Sortilin and SorLA, but similar to its close
relative SorCS1, SorCS3 bound neither RAP, neurotensin nor
its own propeptide. Since the Vps10p-domain of Sortilin binds
both the prodomain and the mature form of NGF, and as Sor-
LA interacts with GDNF [23], we next tested a series of neuro-
trophic factors and their prodomains for binding. As depicted
in Fig. 2, SorCS3 interacted with NGF as well as with its
prodomain. Both ligands bind with an estimated Kd of about
35 nM, which means that mature NGF binds equally well to
SorCS3 and Sortilin, whereas the prodomain has a 5–10-fold
higher aﬃnity for Sortilin as determined from the present
and previous results [16]. Additional experiments (Fig. 2, lower
panel) show that SorCS3 also interacts with the (uncleaved)
NGF-precursor with an aﬃnity which is 5–10-fold lower than
that of Sortilin. In contrast, SorCS3 exhibits little or no bind-
ing of BDNF, NT3, NT4 and GDNF, or of their respective
prodomains (Kds > 1 lM).PAGE and silverstaining (inset, upper panel).
Fig. 3. SorCS3 propeptide cleavage is not required for ligand binding.
Cleavage-resistant s-SorCS3pro-mut and wt s-SorCS3 (inset) were
puriﬁed, immobilized and tested in parallel for binding of the NGF
(GST-)prodomain. Sensorgrams obtained by plasmon resonance
analysis at various concentrations of ligand are shown and estimated
Kd-values are indicated.3.3. Propeptide cleavage is not a requirement for ligand binding
to SorCS3
Sortilin and SorLA bind their respective propeptides and de-
pend on propeptide cleavage for interaction with ligands. In
contrast, SorCS3 does not bind its own propeptide and might
therefore bind ligands irrespective of cleavage. To clarify this,
we expressed a mutant s-SorCS3 carrying a disrupted motif for
cleavage. The convertase-resistant precursor, s-SorCS3pro-mut,
was puriﬁed from culture medium and tested for ligand bind-
ing in parallel with wt s-SorCS3. The plasmon resonance anal-
ysis (Fig. 3) shows that the two s-SorCS3 species bind the
NGF-propeptide with similar aﬃnities. It can be concluded
that cleavage and removal of the propeptide is not a require-
ment for SorCS3 mediated ligand binding.
In separate experiments the rates of secretion of wt s-SorCS3
and of a corresponding construct missing the propeptide (trun-
cated at A93) were compared by chase of minireceptors in cells
and medium of biolabelled cultures (not shown). The cells were
labelled in the presence of BFA, washed and reincubated in
fresh unsupplemented medium (zero time), and at given times
labelled minireceptors were precipitated from medium and
lysed cells. As determined by this procedure the two constructs
were secreted at similar rates. Thus, the propeptide serves nei-
ther to prevent ligand binding nor to facilitate processing of
the newly synthesized SorCS3.3.4. SorCS3 predominates on the surface membrane
Full-length SorCS3 is mainly expressed on the cell mem-
brane and after biotinylation of proteins exposed on transfec-
ted cells 64.3% ± 18 (n = 3) of the cellular SorCS3 was
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tochemical analysis of SorCS3 transfectants shows a pro-
nounced receptor-speciﬁc staining on the plasma membrane
(Fig. 4A, left panel). IL2R/SorCS3 chimeric receptors compris-
ing the wt SorCS3 tail shows a similar distribution (Fig. 4A,
right panel) and as CHO-cells neither express IL2R nor react
with anti-IL2R (anti-CD25), this construct was used for anal-Fig. 4. Subcellular distribution of full-length SorCS3 and chimeric
IL2R/SorCS3 (A) and internalization of IL2R/SorCS3 chimeras (B
and C). (A) CHO-transfectants expressing wt SorCS3 or IL2R/SorCS3
(carrying the cd of SorCS3) were ﬁxed and stained using rabbit anti-
SorCS3 or mouse anti-IL2R as primary antibodies and Alexa 488
conjugated-goat anti-rabbit or anti-mouse, respectively, as secondary
antibodies. After binding of anti-IL2R (B) or 125I-labelled anti-IL2R
(C) at 4 C, CHO-cells transfected with IL2R/SorCS3 were washed and
reincubated (zero time) in warm medium. (B) At the times indicated,
the cells were ﬁxed and receptor:antibody complexes were stained by
secondary anti-mouse antibodies, and analyzed by confocal micros-
copy. (C) At the times indicated, internalization was determined as the
amount of cell-associated radioactivity that was not released upon
incubation at pH 2.5. Each point represents mean of triplicates and all
values are shown relative to total cell-associated radioactivity at zero
time.ysis of receptor mediated endocytosis. It appears that anti-
IL2R bound to the IL2/SorCS3 chimera at 4 C is internalized
by CHO-transfectants at 37 C (Fig. 4B). As determined by
125I-labelled anti-IL2R about 30% (29.4% ± 2.8, n = 3) of the
antibody was internalized (i.e., not dissociable at pH 2.5) with-
in 60 min (Fig. 4C). Surprisingly, disruption of the potential
sorting sites Y10AQV13 (to A10AQV or YAQA13) and
E45PEELL50 (to EPEEA49A50) gave similar results, i.e.,
27.3% ± 4.9, 36.1% ± 7.0 and 37.3% ± 5.8, respectively. Thus,
it can be concluded that although the cd of SorCS3 may medi-
ate endocytosis, it is much less eﬃcient than the Sortilin and
SorLA cds [11,24], and does not depend on classical motifs
for internalization.
Finally, a MPR300/SorCS3 chimera was expressed in man-
nose 6-phosphate receptor deﬁcient cells that, in the absence
of sorting receptors, release their newly synthesized lysosomal
enzymes to the medium. The chimera binds enzymes via its
MPR300 luminal domain, but in the presence of mannose 6-
phosphate, which prevents (re)uptake from the medium, it
failed to restore sorting and to prevent secretion of the
MPR300 ligands b-glucoronidase and b-lactosidase. Thus,
after 20 h of culture both transfected (MRP300/SORCS3)
and untransfected mpr-cells had released most of their b-
glucoronidase (72.1% and 81.6%) and, respectively, b-lactosi-
dase (71.1% and 87.1%) to the medium, whereas less than
22% was released by mpr-cells transfected with wt-
MRP300. It follows that SorCS3, unlike Sortilin, is not en-
gaged in Golgi-endosome traﬃcking.4. Discussion
The functions of the SorCS-subgroup of Vps10p-domain
receptors are unclariﬁed and current knowledge is based on
a single report on SorCS1 expression [19]. Here, we report
the ﬁrst study of expressed SorCS3. We ﬁnd that SorCS3 sim-
ilar to previously examined Vps10p-domain receptors is syn-
thesized as a precursor molecule that is converted to its
mature form by N-terminal propeptide cleavage. In contrast
to Sortilin and SorLA, however, SorCS3 does not bind its
own propeptide and, notably, does not depend on propeptide
cleavage for interaction with ligands. In addition, we demon-
strate that SorCS3 like SorLA, but unlike Sortilin, is normally
processed in the absence of a propeptide [23]. These ﬁndings
suggest that the SorCS3 propeptide may be functionally redun-
dant and establish that the function of the propeptide varies
between the family receptors.
Another interesting diﬀerence between SorCS3, Sortilin and
SorLA concerns receptor localization and sorting. Unlike its
two relatives [11,12], SorCS3 predominates on the cell surface,
its cd conveys only slow internalization and it does not partake
in Golgi-endosome traﬃcking. These results evidence that
SorCS3 is not involved in intracellular sorting or transport
of proteins but, more likely, participates in functional events
at the surface membrane. In that respect, its binding of NGF
and proNGF is particularly interesting. Thus, Sortilin also
binds the prodomain of the NGF precursor and this interac-
tion was recently shown to facilitate proNGF induction of
p75NTR mediated neuronal cell death [16]. Future studies will
determine if SorCS3 similar to Sortilin can engage in a com-
plex with p75NTR, but in view of its high expression on the cell
1176 U.B. Westergaard et al. / FEBS Letters 579 (2005) 1172–1176membrane it is conceivable that SorCS3 is implicated in
proNGF mediated signalling.
In summary, we ﬁnd SorCS3 to be a neurotrophin binding
receptor that diﬀers distinctly from its relatives Sortilin and
SorLA in terms of propeptide function and intracellular
traﬃcking.
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